Abstract: The present invention relates to a fixed bed, for example for the isolation and/or purification of components originating from a biological system, which fixed bed comprises magnetic beads and a magnetizable fabric arranged at least in part in the fixed bed, a fluidized bed-fixed bed, which comprises the fixed bed of the invention after application of an alternating magnetic field, and also to a process for the isolation and/or purification of components originating from a biological system.

Abstract: The present invention relates to a fixed bed, for example for the isolation and/or purification of components originating from a biological system, which fixed bed comprises magnetic beads and a magnetizable fabric arranged at least in part in the fixed bed, a fluidized bed-fixed bed, which comprises the fixed bed of the invention after application of an alternating magnetic field, and also to a process for the isolation and/or purification of components originating from a biological system.

Abstract: A rheometer comprises a container for receiving a material sample to be investigated, and a rotary driven rotor which can be immersed at least partially into the material sample. At least sections of an inner wall of the container are provided with a profile in order to prevent formation of a sliding layer between the material to be investigated and the inner wall. The profile is thereby formed by at least one, in particular, several profiling elements which are exchangeably held on the container.

Abstract: In a process for producing an SCR catalyst for the selective reduction of NOx in NOx-containing exhaust gases of internal combustion engines, a support layer is applied to a substrate body. An iron salt dissolved in a liquid is applied to the support layer in such an amount that no excess of iron salt is present.

Abstract: A monolithic active pixel dosimeter, provided with at least a sensing cell, having at least a junction sensing element. The junction sensing element includes a sensing region, having a first type of conductivity, and a charge collecting region, contiguous to the sensing region and having a second type of conductivity. The sensing cell further includes an ohmic region at least partially overlapping and extending laterally outside the charge collecting region, and an annular insulating region, abutting the ohmic region, so as to form an insulating junction surrounding both the ohmic region and the charge collection region.

Abstract: The invention relates to a method of determining material properties of a contact formed between a measurement tip of a microscopic probe and a sample surface of a sample material. According to the method, a distance modulation is applied for modulating a distance between a support of the microscopic probe end the sample surface in a direction essentially normal to the sample surface and wherein a normal force signal indicative of a normal force is measured and demodulated. In the method it is proposed that the material properties be determined using measurement data comprised in the demodulated normal force signal and related to a (concave) buckling deformation of the microscopic probe relative to and away from the sample surface.

Abstract: A rheometer comprises a container for receiving a material sample to be investigated, and a rotary driven rotor which can be immersed at least partially into the material sample. At least sections of an inner wall of the container are provided with a profile in order to prevent formation of a sliding layer between the material to be investigated and the inner wall. The profile is thereby formed by at least one, in particular, several profiling elements which are exchangeably held on the container.

Abstract: A laser with a decoupling device for emitting a laser output depending on at least one influenceable parameter and a mode-coupling device for coupling a plurality of the laserable modes of the resonator. A detector is provided for detecting a value related to the emitted laser output and a parameter varying means for varying the at least one parameter in response to the detected value.

Abstract: The inventon relates to antibodies that react with a variant epilope in the extracellular region of a variant CD44 polypeptide, wherein the variant epitope has the amino acid sequence:I S S T I S T T P R A P D H T K Q N Q D W T Q W N P S H S N P EV L L Q T T T R M T D V D R N G T T A Y E G N W N P E A H P P LI H H E H H E E E E T P H S T S T I O A T P S S T T E E T A T QK E Q W F G N R W H E G Y R Q T P R E D S H S T T G T A A A S AH T S H P M Q G R T T P S P E D S S W T D F F N P I S H P M G RG H Q A G R R (residues 53-219 of SEQ ID NO:4). Methods of using the antibodies to identify variant epitopes also are provided.

Abstract: A monoclonal antibody (MAb1.1ASML) directed against a surface glycoprotein of the metastasizing rat pancreatic carcinoma cell line BSp73ASML, was used to identify and isolate a complementary DNA (cDNA) clone capable of encoding for a glycoprotein with partial homology to CD44, a presumed adhesion molecule. This clone, which was subsequently designated pMeta-1, contains an additional extracellular domain of 162 amino acids inserted into the CD44 protein between amino acid positions 223 and 247 (by analogy to human and murine CD44). This new variant was expressed only in the metastasizing cell lines of two rat tumors, the pancreatic carcinoma BSp73 and the mammary adenocarcinoma 13762NF; it was not expressed in non-metastasizing tumor cell lines nor in normal rat tissues. Overexpression of pMeta-1 in the nonmetastasizing BSp73AS cell line suffices to establish full metastatic behavior. The variant-specific rat CD44 sequence was used to isolate a cDNA clone encoding for a human homologue as well.

Abstract: The presence of certain extracellular regions ("ECR") from human and rat variants of the CD44 membrane glycoprotein have been found to be associated with metastasis ability in tumor cells. Isolated polynucleotides encoding the ECRs permit expression of the ECR polypeptide, which in turn can be used as an antigen to obtain monoclonal antibodies that recognize the ECR polypeptide. The anti-ECR monoclonal antibodies have the ability to prevent metastasis by tumor cells that would otherwise metastasize and spread.